I just submitted comments on behalf of IWF on President Trump's proposal for using an International Price indexing for Medicare Drugs. I sympathize with the desire to reduce drug prices, but price controls are the wrong way to do it and will hurt the people we want to help.
I've written more in-depth about the inherent problems in Medicare's pricing model here. The current model could be improved, but policymakers should take note that too-low prices can do harm. Patients might think that there is no such thing as too low a price(!) but the tradeoff could be reduced access to life-saving drugs or less innovation. Read my full comment from IWF to the Centers for Medicare and Medicaid Services below.